Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for behavioral disturbances in dementia
NCT00249145Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 1995
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in Alzheimer's disease (AD), vascular dementia, mixed dementia, sponsored by Janssen Pharmaceutical. Started Apr 1995; status: completed.
02
Drugs
risperidone
03
Conditions
Alzheimer's disease (AD)vascular dementiamixed dementia
Beyond the preview
Go deeper on NCT00249145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249145.